Form 4: Bausch & Lomb director awarded 1,642 RSUs

Bausch & Lomb (BLCO) director Russel C. Robertson reported an award of 1,642 RSUs at $15.6 on November 14, 2025, bringing direct ownership to 66,556 shares.

Summary

• Director Russel C. Robertson reported an equity award on 11/14/2025 coded as “A” for acquisition.
• 1,642 common shares were acquired via restricted share units (RSUs) at a reported price of $15.6 per share.
• Post-transaction beneficial ownership stands at 66,556 shares, held directly.
• The footnote clarifies the award consists of RSUs, each representing a contingent right to receive one common share of Bausch + Lomb Corporation.
• The filing was signed by attorney-in-fact Debra E. Levin on 11/18/2025.

Sentiment

Score: 6

Explanation: Routine, modest director RSU grant that modestly improves alignment with shareholders; no operational or financial performance implications.

Positives

• Director equity award aligns board member incentives with shareholder interests.
• Transparent disclosure of updated beneficial ownership (66,556 shares, direct).
• Award size is modest (1,642 units), implying minimal dilution.

Negatives

• Incremental dilution from issuance of additional equity (1,642 shares).
• No details on vesting schedule or performance conditions, limiting visibility into alignment and retention mechanics.

Future Outlook

NA

Industry Context

Equity awards to independent directors are standard across medical technology and eye care peers; modest-sized RSU grants are commonly used for annual board compensation and to align director interests with shareholders.

Comparison to Industry Standards

• Relative to peers such as Alcon (ALC) and CooperCompanies (COO), a ~1.6k-share RSU grant at $15.6 (~$25.6k notional) appears modest, consistent with routine director retainer equity rather than a large strategic award.
• The use of RSUs (versus options) is in line with governance best practices emphasizing ownership and downside alignment for non-employee directors.

Stakeholder Impact

• Shareholders: immaterial dilution from 1,642 additional shares.
• Governance: continued alignment of director incentives with long-term equity value.
• Employees and customers: no direct impact disclosed.

Key Dates

Keywords

Bausch & Lomb, BLCO, Form 4, insider transaction, restricted share units, RSU grant, director compensation, beneficial ownership, Russel C. Robertson, ophthalmic devices